New class of genes that serve as an Achilles' heel for many forms of cancer have been discovered by scientists at Dana-Farber Cancer Institute and the Broad Institute of MIT and Harvard.
The researchers identified 56 such genes, only a few of which had previously been identified as potential targets for cancer therapy. Unlike most such targets, these genes don't cause normal cells to turn cancerous. Instead, they are essential to all cells but have been disrupted as cancer progresses.
"One of the hallmarks of cancer is genomic instability, in which entire sections of chromosomes can be lost or duplicated many times over. The result is that genes residing in those areas are either deleted or significantly over-copied," said Dana-Farber's Rameen Beroukhim, MD, PhD, who co-led the study.
This roiling of the chromosomes often leads to partial loss of essential genes, leaving cancer cells with barely enough of these genes to survive. Such genes become lifelines for tumor cells. Blocking them with drug molecules is far more likely to harm cancer cells than normal cells.
One way that cancers lose these essential genes is by the loss of nearby tumor suppressor genes, which act as a brake against runaway cell growth. Whereas normal cells harbor two copies of each gene, cancers often lose at least one copy of important tumor suppressor genes, unleashing cell proliferation.
"When tumor suppressor genes are lost, it's common for several nearby genes-which play no role in cancer development-to be lost as well," explained the study's co-senior author William Hahn, MD, PhD, of Dana-Farber.
Nearly 20 years ago, a scientist published a theory that blocking the remaining copies of these neighboring genes would cripple cancer cells' ability to grow and divide.
The author of that paper, in 1993, was Emil "Tom" Frei III, MD, who was Dana-Farber's director and physician-in-chief from 1972-1991. At the time, the tools didn't exist to determine whether the theory was valid. Only now, with the development of cutting-edge genomic technology, were researchers able to put it to the test.
Investigators began by scanning more than 3,100 samples of different types of cancers, and found that most were missing copies of genes across wide stretches of the genome. They then analyzed data from Project Achilles, a Dana-Farber research effort that has uncovered hundreds of genes critical to the reproduction of cancer cells.
Researchers combined both sets of data to find instances where the loss of one copy of a gene rendered the remaining copy especially important to the cancer cell. From an initial pool of 5,312 genes, researchers identified 56 that met the desired criteria. They dubbed them CYCLOPS genes (for Copy number alterations Yielding Cancer Liabilities Owing to Partial losS), evoking the mythical giant that was dependent on its one eye rather than the normal complement of two.
When researchers checked to see if any of the CYCLOPS genes were neighbors of missing tumor suppressor genes, as Frei had hypothesized two decades earlier, they found that, indeed, many were.
Investigators next surveyed the CYCLOPS genes to see if they have similar or divergent functions within the cell.
"We found that they're heavily involved in the components of three critical cell structures: the spliceosome, the ribosome-which use genetic information to construct proteins for the cell-and the proteasome, which is a vital protein machine that disposes of unneeded protein material. This suggests that they're required for cell proliferation or survival," Hahn noted.
When the researchers ranked the 56 CYCLOPS genes by the degree to which the cancer cells were dependent on them, the gene that topped the list was PSMC2.
When they administered a PSMC2-blocking agent to mice whose tumors lacked a copy of the PSMC2 gene, the tumors shrank dramatically.
"It was a powerful demonstration of the potential of CYCLOPS genes to serve as targets for cancer therapies," Beroukhim explained.
The fact that CYCLOPS genes are often neighbors of tumor suppressor genes makes them even more attractive as drug targets, the study authors say.
The research was reported in the latest issue of the journal Cell.